Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 31 August 2018


Posted on: 31 Aug 18

Company Release no. 16/2018

To: NASDAQ Copenhagen A/S                                                

Copenhagen, Denmark, 31 August 2018


Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of
31 August 2018


Veloxis Pharmaceuticals A/S announces, in accordance with Section 10 of the Danish Statutory Order on Issuers’ Disclosure Obligations, the total number of shares and voting rights in the Company at the end of a calendar month in which changes to the share capital have occurred.

With reference to Company Release no. 15/2018 dated 23 August 2018 informing of an increase in the share capital and the voting rights after exercise of employee warrants, the table below provides the total number of shares and voting rights in Veloxis as of 31 March 2018. 

            Date                                            Total Number of Shares                       Share Capital                Total Number of Votes
                 (nominal value of DKK 0.10 each)        (nominal value in DKK)
     31 August 2018                                         1,712,838,531                            171,283,853.10                  1,712,838,531


For more information, please contact:

Craig Alexander Collard
President & CEO          
Phone: +1 919 591 3090        
Email: cac@veloxis.com


About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients.  A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals, Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA.  Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the Company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs.  The Company is focused on the direct commercialization of Envarsus XR in the U.S., expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.  For further information, please visit www.veloxis.com.

Attachment

GlobeNewswire
globenewswire.com

Last updated on: 31/08/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.